国际药物警戒最新进展与启示

doi:10.19803/j.1672-8629.2020.12.04

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (12): 867-870.
DOI: 10.19803/j.1672-8629.2020.12.04

国际药物警戒最新进展与启示

陈锋

国家药品监督管理局信息中心,北京 100044

收稿日期:2020-06-10 修回日期:2020-12-07 出版日期:2020-12-15 发布日期:2020-12-07
作者简介:陈锋,男,博士,研究员,医药信息。

Latest Development of International Pharmacovigilance and Its Implications

CHEN Feng

Center for Information,NMPA,Beijing 100044,China

Received:2020-06-10 Revised:2020-12-07 Online:2020-12-15 Published:2020-12-07

摘要/Abstract

摘要： 作为全球药物警戒发展风向标的世界卫生组织国际药物监测项目成员国年会,是关注国际药物警戒热点与最新进展的重要窗口。本文以2019年召开的第42届年会为背景,分析了当前国际药物警戒最新发展动向及相关启示,认为药物警戒工作范围从不良反应监测拓展到药物滥用、误用和用药错误检测、报告与预防,工作重心正逐步从以药品安全为中心转向患者安全为中心,迫切需要进一步增强社会药物警戒意识和简化公众参与途径;另外,以人工智能为代表的新一代信息技术在药物警戒领域应用中正在取得突破,积极推进智慧监管和智慧安全监测已成国际共识。

关键词: 药物警戒意识, 用药错误, 智慧安全监测, 人工智能

Abstract: As a predictor of development of global pharmacovigilance, the Annual Meeting of WHO Program of International Drug Monitoring (PIDM) is an important event for us to find out hotspots and latest progress in pharmacovigilance worldwide. Based on the agenda of the 42nd Annual Conference held in 2019, this paper analyzes the latest developments of global pharmacovigilance and implications for China. It is believed that the scope of pharmacovigilance has been expanded from adverse reaction monitoring to the detection, reporting and prevention of drug abuse, misuse and medication errors, and that the focus is gradually shifting from drug safety to patient safety. Therefore, there is an urgent need to continue to enhance the awareness of social drug vigilance and streamline public participation. In addition, the application of new generation information technology represented by artificial intelligence (AI) in the field of pharmacovigilance is making a breakthrough, and it has become an international consensus to actively promote smart supervision and smart safety surveillance.

Key words: pharmacovigilance awareness, medication error, smart safety surveillance, artificial intelligence

中图分类号:

R969.3

陈锋. 国际药物警戒最新进展与启示[J]. 中国药物警戒, 2020, 17(12): 867-870.

CHEN Feng. Latest Development of International Pharmacovigilance and Its Implications[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 867-870.

参考文献

[1] Liu P.Implement "the Four Strictest Principles" and Strictly Observe Drug Safety-Publicity and Implementation of the Newly Revised Drug Administration Law of the People' s Republic of China[J].China Pharmaceuticals(中国药业),2019,28(24):1-3.
[2] Song HL.The construction of the vaccine management system and the innovation of the legal system-legislative interpretation of the "People's Republic of China Vaccine Management Law"[J].China Food Drug Administration(中国食品药品监管),2019(7):4-12.
[3] NMPA.National adverse drug reaction monitoring and evaluation work video conference held[EB/OL].(2020-05-19)[2020-06-06].http://www.nmpa.gov.cn/WS04/CL2056/377524.html.
[4] Cao LY,Wu GZ,Tian CH.Strengthen international comm-unication &cooperation to promote global drug monitoring[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2006,3(3):150-152.
[5] World Health Organization (WHO).42nd Annual Meeting of Representatives of National Pharmaco vigilance Centres Participating in the WHO Progr amme for International Drug Monitoring[J].WHO Pharmaceuticals Newsletter,2019(6):25.
[6] World Health Organization (WHO).WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory systems [EB/OL].[2020-06-06].https://www.who.int/medicines/regulation/benchm-arking_tool/en/.
[7] Caster O,Aoki Y,Gattepaille LM,et al.Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets:Recom mendations for Limiting False-Positive Associations[J].Drug Safety,2020(43):479-487.
[8] Uppsala Monitoring Center.What is VigiBase?[EB/OL][2020-06-06].https://www.who-umc.org/vigibase/vigibase/.
[9] U.S.Food and Drug Administration (FDA).MedWatch:The FDA Safety Information and Adverse Event Reporting Program [EB/OL].[2020-06-06].https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.
[10] U.S.Food and Drug Administration (FDA).FDA Adverse Event Reporting System[EB/OL].[2020-06-06].https://www.fda.gov/drugsdrug-approvals-and-databases/fda-adverse-event-reporting-system-faers.
[11] Thomas L,Carol P,Oanh D,et al.Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology[J].Journal of Biomedical Informatics,2018,83(7):73-86.
[12] Jiang J,Hou YF,Liu XJ,et al.Overview of adverse drug reaction signal detection methods[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2010,7(2):78-80.
[13] World Health Organization (WHO).Meeting postponed.[EB/OL].[2020-06-06].https://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/ICDRA2020/en/.http://www.nmpa.gov.cn/WS04/CL2199/337981.html.
[14] NMPA.Notice of the State Drug Administration on printing and distributing the action plan of the State Drug Administration on accelerating the promotion of smart drug supervision[EB/OL].(2020-05-24)[2020-06-06].http://www.nmpa.gov.cn/WS04/CL2199/337981.html.
[15] NMPA.The State Food and Drug Administration launches China's drug regulatory scientific action plan[EB/OL].(2020-04-30)[2020-06-06].http://www.nmpa.gov.cn/WS04/CL2056/337150.html.

国际药物警戒最新进展与启示

Latest Development of International Pharmacovigilance and Its Implications

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	袁偲偲, 王广燕, 李轶凡, 李瑞莲, 杜博冉, 冯欣. 基于失效模式与效应分析的麻精药品临床管理安全相关风险因素研究[J]. 中国药物警戒, 2023, 20(9): 1027-1030.
[3]	张青霞, 周柳君, 李晓玲, 王育琴. 老年人头孢哌酮舒巴坦用药错误报告分析与建议[J]. 中国药物警戒, 2023, 20(5): 574-578.
[4]	丁倩, 李博宇, 张青霞. 硝酸甘油开封后贮藏风险调查与防范[J]. 中国药物警戒, 2023, 20(3): 326-330.
[5]	王涛, 郑明节, 刘红亮, 王青, 沈传勇. 人工智能在美国药物警戒中的应用现状及启示[J]. 中国药物警戒, 2023, 20(10): 1129-1133.
[6]	张青霞, 江永贤, 李根, 闫素英, 王育琴. 全国临床安全用药监测网贮藏用药错误案例分析及风险点防范[J]. 中国药物警戒, 2022, 19(9): 1040-1044.
[7]	邵晨, 张青霞, 闫素英, 王育琴. 他汀类药物1028例用药错误报告分析及防范策略[J]. 中国药物警戒, 2022, 19(6): 645-648.
[8]	张青霞, 丁倩, 闫素英, 王育琴. 达比加群酯和利伐沙班用药错误报告分析及防范策略[J]. 中国药物警戒, 2022, 19(12): 1372-1375.
[9]	张青霞, 江永贤, 董月鑫, 咸颖, 王育琴, 闫素英. 胰岛素贮藏风险调查和典型用药错误案例分析与防范[J]. 中国药物警戒, 2022, 19(11): 1242-1245.
[10]	宋美华, 张婷玉, 葛子若, 徐艳利, 陈志海, 钱芳. 静注新型冠状病毒肺炎人免疫球蛋白（pH4）治疗新型冠状病毒肺炎的疗效观察[J]. 中国药物警戒, 2021, 18(10): 905-909.
[11]	刘琛, 褚燕琦, 闫素英, 金超, 刘彤, 邢丽秋, 张晓. 93例依达拉奉注射液药品不良反应报告分析[J]. 中国药物警戒, 2019, 16(3): 174-178.
[12]	李岚, 夏东胜, 田春华. 甲氨蝶呤误用风险分析及对药物警戒的启示[J]. 中国药物警戒, 2017, 14(9): 538-540.
[13]	祁献芳,张龙,陈晓萌,孙俊. 我院住院患者用药错误分析[J]. 中国药物警戒, 2017, 14(12): 760-763.
[14]	庄红艳, 郝红兵, 刘珊珊, 果伟, 马辛, 李华维, 池伟, 张红玉. 69例精神科用药错误报告分析[J]. 中国药物警戒, 2017, 14(1): 54-58.
[15]	朱忱崔璨, 李晓玲, 闫素英王育琴. 281例抗肿瘤药物用药错误分析[J]. 中国药物警戒, 2017, 14(1): 40-44.